Cargando…
Paclitaxel resistance is mediated by NF-κB on mesenchymal primary breast cancer cells
Paclitaxel has been used widely to treat breast cancer and other types of cancer. However, resistance is a major cause of failure for treatment and results in cancer progression. The present study investigated the association between paclitaxel resistance and the mesenchymal phenotype, using a model...
Autores principales: | Esparza-López, José, Longoria, Ossian, De La Cruz-Escobar, Eliseo Neftali, Garibay-Díaz, Julio Cesar, León-Rodríguez, Eucario, De Jesús Ibarra-Sánchez, María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721864/ https://www.ncbi.nlm.nih.gov/pubmed/34992683 http://dx.doi.org/10.3892/ol.2021.13168 |
Ejemplares similares
-
Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways
por: Esparza-López, José, et al.
Publicado: (2019) -
Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases
por: Esparza-López, José, et al.
Publicado: (2016) -
NF-κB, Mesenchymal Differentiation and Glioblastoma
por: Yamini, Bakhtiar
Publicado: (2018) -
Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
por: Wang, Panpan, et al.
Publicado: (2020) -
SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway
por: Khan, Shahanshah, et al.
Publicado: (2021)